Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ME
ME logo

ME Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
207.53M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
-63.09M
EV/OCF(TTM)
--
P/S(TTM)
--
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Show More

Events Timeline

(ET)
2025-06-30
08:02:45
23andMe receives court approval for sale to TTAM Research Institute
select
2025-06-11 (ET)
2025-06-11
05:47:43
27 states, DC, sue 23andMe over sale of DNA data, NY Times reports
select
link
2025-06-06 (ET)
2025-06-06
05:44:40
23andMe to hold second auction for DNA data, Bloomberg reports
select
link
2025-05-27 (ET)
2025-05-27
12:48:38
23andMe announces intent to voluntarily delist from Nasdaq, deregister with SEC
select
2025-05-19 (ET)
2025-05-19
07:10:34
Regeneron enters asset purchase agreement to acquire 23andMe for $256M
select
2025-05-19
07:07:19
Regeneron to acquire 23andMe for $256M in court-supervised sale
select
2025-03-26 (ET)
2025-03-26
19:02:22
23andMe confirms all potential buyers must comply with privacy policy
select
2025-03-25 (ET)
2025-03-25
05:59:43
23andMe customers rush to delete data after bankruptcy filing, WSJ reports
select
link
2025-03-24 (ET)
2025-03-24
05:48:55
23andMe CEO Anne Wojcicki resigns, Joe Selsavage named interim CEO
select

News

Yahoo Finance
9.0
2025-06-04Yahoo Finance
23andMe seeks new bids after $305 million offer from its co-founder
  • Bankruptcy and Bidding: 23andMe, a bankrupt genetic testing company, is seeking to reopen bidding for its assets after receiving a $305 million offer from co-founder Anne Wojcicki, surpassing the previous lead bid of $256 million from Regeneron Pharmaceuticals.

  • Concerns Over Data Sale: The bankruptcy sale includes over 15 million customer DNA profiles, raising concerns among U.S. lawmakers about the potential sale of sensitive genetic data following a significant data breach that exposed personal information of millions.

TipRanks
9.0
2025-04-02TipRanks
Blockchain Projects Race to Rescue DNA Data as 23andMe Declares Bankruptcy
  • 23andMe Bankruptcy and Data Concerns: 23andMe is facing bankruptcy, allowing the potential sale of 15 million users' genetic data, prompting privacy experts to advise users to delete their information before it can be sold.

  • Emergence of Blockchain Solutions: In response, blockchain projects like Genomes.io and GenoBank are offering decentralized alternatives for users to control their DNA data, although challenges such as high costs and privacy risks remain.

NASDAQ.COM
6.5
2025-03-28NASDAQ.COM
How to Tune Out Market Noise
  • Market Uncertainty and Tariffs: The podcast discusses the impact of upcoming tariffs set to be imposed by the U.S. on various countries, which has contributed to market volatility. Analysts suggest that investors should accept this uncertainty as a part of the investing landscape and focus on understanding different industries.

  • MGM Resorts and Online Sports Betting: MGM Resorts is exploring opportunities in online sports betting through its partnership with BetMGM, while also expanding its operations globally, including significant investments in Japan and Dubai. Analysts believe that despite current challenges in Las Vegas, MGM's core business remains strong and offers long-term growth potential.

Newsfilter
9.0
2025-03-26Newsfilter
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
  • Company Bankruptcy Filing: 23andMe has filed for voluntary Chapter 11 bankruptcy and received court approval for initial motions, including employee wage payments and a $35 million debtor-in-possession financing facility to support ongoing operations.

  • Asset Sale Process: The company is authorized to sell substantially all of its assets through a structured auction process while maintaining customer data privacy policies, with a second court hearing scheduled for April 22 to consider further relief requests.

CNBC
9.0
2025-03-26CNBC
23andMe co-founder lashes out at CEO Wojcicki after bankruptcy filing, says board lacked oversight
  • 23andMe's Bankruptcy and Leadership Issues: Co-founder Linda Avey expressed her frustration over 23andMe's decline into Chapter 11 bankruptcy, attributing the company's struggles to a lack of consumer-focused product development and governance issues following her departure in 2009.

  • Future Plans and Governance Concerns: Despite the bankruptcy, former CEO Anne Wojcicki intends to pursue the company as an independent bidder, while Avey highlights the importance of balancing founder control with board oversight to avoid similar pitfalls in the future.

Benzinga
6.5
2025-03-26Benzinga
Cybersecurity Stocks To Outperform, It's The 'One Line Item That No Company In The World Is Cutting': Josh Brown
  • Cybersecurity Stocks Performance: Josh Brown from Ritholtz Wealth Management predicts that cybersecurity stocks will continue to outperform the broader tech sector due to their essential nature, with companies unlikely to cut cybersecurity spending even in a recession. The five largest U.S. cybersecurity stocks have risen about 12% year-to-date.

  • Impact of Data Breaches: The recent bankruptcy of 23andMe following a data breach highlights the severe consequences of cybersecurity threats on businesses, reinforcing the demand for cybersecurity solutions and suggesting that this trend will persist throughout the year.

Wall Street analysts forecast ME stock price to rise
0 Analyst Rating
Wall Street analysts forecast ME stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for 23andMe Holding Co. (ME.O) is -0.06, compared to its 5-year average forward P/E of -5.39. For a more detailed relative valuation and DCF analysis to assess 23andMe Holding Co.'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.39
Current PE
-0.06
Overvalued PE
0.75
Undervalued PE
-11.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.68
Current EV/EBITDA
0.01
Overvalued EV/EBITDA
2.91
Undervalued EV/EBITDA
-12.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.38
Current PS
0.05
Overvalued PS
8.82
Undervalued PS
-0.06

Financials

AI Analysis
Annual
Quarterly

Whales Holding ME

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is 23andMe Holding Co. (ME) stock price today?

The current price of ME is 0 USD — it has increased 0

What is 23andMe Holding Co. (ME)'s business?

23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

What is the price predicton of ME Stock?

Wall Street analysts forecast ME stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ME is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is 23andMe Holding Co. (ME)'s revenue for the last quarter?

23andMe Holding Co. revenue for the last quarter amounts to 60.26M USD, increased 34.67

What is 23andMe Holding Co. (ME)'s earnings per share (EPS) for the last quarter?

23andMe Holding Co.. EPS for the last quarter amounts to -1.73 USD, decreased -85.03

How many employees does 23andMe Holding Co. (ME). have?

23andMe Holding Co. (ME) has 769 emplpoyees as of June 19 2026.

What is 23andMe Holding Co. (ME) market cap?

Today ME has the market capitalization of 207.53M USD.